Clinical standards for the management of adverse effects during treatment for TB

Singh, Kasha; Carvalho, Anna Cristina Calçada; Centis, Rosella; Ambrosio, Leire; Migliori, Giovanni Battista; Mpagama, Stellah; Nguyen, B C; Aarnoutse, Rob E.; Aleksa, Alena; Altena, Richard van; Bhavani, Perumal Kannabiran; Bolhuis, Mathieu S.; Borisov, Sergey; Boveneind-Vrubleuskaya, Natascha van 't; Bruchfeld, Judith; Caminero, José A.; Carvalho, Isabel; Cho, J G; Forsman, Lina Davies; Dedicoat, Martin; Dheda, Keertan; Dooley, Kelly E.; Furin, Jennifer; García-García, José María; Garcia-Prats, Anthony J.; Hesseling, Anneke C.; Heysell, Scott K; Hu, Yi; Kim, H Y; Manga, Selene; Marais, Ben J.; Mărgineanu, Ioana; Märtson, Anne-Grete; Torrico, Marcela Muňoz; Nataprawira, Heda Melinda; Nunes, Eduardo; Ong, Catherine W.M.; Otto-Knapp, Ralf; Palmero, Domingo; Peloquin, Charles A.; Rendón, Adrián; Silva, D Rossato; Ruslami, Rovina; Saktiawati, Antonia Morita Iswari; Santoso, Prayudi; Schaaf, H. Simon; Seaworth, Barbara; Keutzer, Lina; Singla, Rupak; Skrahina, Alena; Solovič, Ivan; Srivastava, Shashikant; Stocker, Sophie L.; Sturkenboom, Marieke G G; Svensson, Elin M; Tadolini, Marina; Thomas, Tania A; Tiberi, Simon; Trubiano, Jason A; Udwadia, Z F; Verhage, A R; Vu, Dinh Hoa; Akkerman, Onno W.; Alffenaar, Jan-Willem; Denholm, Justin T.

doi:10.5588/ijtld.23.0078

Cited by 10 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Although only serious ADRs need to be reported, healthcare professionals should be aware of their patients' experience as ADRs can reduce adherence. 17 It is important to include information about possible ADRs during patient education and counselling sessions at initiation and during treatment, 18 and encourage patients to report them to their healthcare professional at their next visit for appropriate intervention as a part of practising patient-centred care. This is especially important for those with HIV, as the combination of medications may increase the likelihood of ADRs.…”

Section: Discussionmentioning

confidence: 99%

Adverse event reporting practices in drug-resistant tuberculosis facilities across South Africa

Gaida,

Davids,

Sewpaul

2023

Southern African Journal of Infectious Diseases

View full text Add to dashboard Cite

Background: The reporting of adverse drug reactions associated with drug-resistant tuberculosis (DR-TB) medication is important for pharmacovigilance, especially in high-burden countries such as South Africa. With DR-TB treatment being so dynamic, it is important to understand adverse event reporting practices at specialised facilities.Objectives: The study aimed to understand the adverse drug reaction (ADR) reporting practices at DR-TB treatment facilities in South Africa.Method: Interviews were conducted with healthcare workers at specialised DR-TB facilities. This was to collect data on demographics, pharmacovigilance training, and determine attitudes and practices towards reporting adverse events. A checklist was developed to review the most recent adverse event forms captured at the facility.Results: Most participants did not have adverse event reporting training since their initial training but were confident that they could complete a form themselves. Most participants could correctly identify the major adverse events associated with DR-TB medication, but some deemed non-adverse events as plausible. Adverse event report forms were not standardised with most participants deeming further training and regular feedback as reasons to report ADRs.Conclusion: Standardisation of adverse event report forms used and the establishment of regular reporting will increase adverse event reporting at DR-TB facilities. Continuous training, empowerment and expansion of staff categories eligible to report adverse events will enhance and sustain such practice.Contribution: The study highlights challenges faced by healthcare professionals in reporting adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%

Adverse event reporting practices in drug-resistant tuberculosis facilities across South Africa

Gaida,

Davids,

Sewpaul

2023

Southern African Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“… 27 – 31 We have therefore extrapolated from data on other respiratory conditions and previously published clinical standards to inform our approach. 32 – 35 Evidence on post-COVID lung disease is still lacking in areas such as benefits/risks evaluations, and costs and cost-analysis. We present an ‘optimal’ set of standards (recommendations for the best possible approach), but acknowledge that implementing this approach may be difficult in some settings.…”

Section: Aim Of the Clinical Standardsmentioning

confidence: 99%

Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease

Visca,

Centis,

Pontali

et al. 2023

int j tuberc lung dis

View full text Add to dashboard Cite

BACKGROUND: The aim of these clinical standards is to provide guidance on ‘best practice’ care for the diagnosis, treatment and prevention of post-COVID-19 lung disease.METHODS: A panel of international experts representing scientific societies, associations and groups active in post-COVID-19 lung disease was identified; 45 completed a Delphi process. A 5-point Likert scale indicated level of agreement with the draft standards. The final version was approved by consensus (with 100% agreement).RESULTS: Four clinical standards were agreed for patients with a previous history of COVID-19: Standard 1, Patients with sequelae not explained by an alternative diagnosis should be evaluated for possible post-COVID-19 lung disease; Standard 2, Patients with lung function impairment, reduced exercise tolerance, reduced quality of life (QoL) or other relevant signs or ongoing symptoms ≥4 weeks after the onset of first symptoms should be evaluated for treatment and pulmonary rehabilitation (PR); Standard 3, The PR programme should be based on feasibility, effectiveness and cost-effectiveness criteria, organised according to local health services and tailored to an individual patient’s needs; and Standard 4, Each patient undergoing and completing PR should be evaluated to determine its effectiveness and have access to a counselling/health education session.CONCLUSION: This is the first consensus-based set of clinical standards for the diagnosis, treatment and prevention of post-COVID-19 lung disease. Our aim is to improve patient care and QoL by guiding clinicians, programme managers and public health officers in planning and implementing a PR programme to manage post-COVID-19 lung disease.

show abstract

“Why don't we talk about tuberculosis stewardship?”

Riccardi,

Matucci,

Falcone

2024

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Clinical standards for the management of adverse effects during treatment for TB

Cited by 10 publications

References 95 publications

Adverse event reporting practices in drug-resistant tuberculosis facilities across South Africa

Adverse event reporting practices in drug-resistant tuberculosis facilities across South Africa

Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease

“Why don't we talk about tuberculosis stewardship?”

Contact Info

Product

Resources

About